Brian Stidsen Vandahl, PhD’s Post

🚀 Exciting News in Cardiometabolic Research! 🌟 Evotec and Novo Nordisk have launched LAB eN, a groundbreaking translational drug discovery accelerator, featuring three pioneering projects aimed at addressing significant unmet medical needs in cardiometabolic diseases. 🔍 Key Highlights: - Focus on chronic conditions like obesity, metabolic syndrome, and type 1 diabetes. - Collaboration with top-tier institutions including Boston University and Harvard. - Initial Discovery Awards to reach crucial pre-clinical milestones. - Expansion to five prestigious institutions enhances research diversity. This strategic partnership is set to transform innovative academic research into viable therapeutic candidates! 👉 Click the link for more details on this impactful initiative! #CardiometabolicHealth #DrugDiscovery #HealthcareAdvancements #Innovation #NovoNordisk #Pharma #PharmaceuticalCompanies #ResearchCollaboration #MarketAccess #MarketAccessToday

The blood–brain barrier has proven to be a significant obstacle for drug administration in the past. However, being able to traverse this barrier and treat diseases that affect the brain, such as Alzheimer's disease, is getting slightly easier thanks to innovative technology like Aliada Therapeutics' MODEL platform. To learn more about this exciting new tool and the potential impact it may have on therapeutic delivery for brain-related conditions, Joe Petroziello, EVP, Global Medical Affairs & Corporate Development, MJH Life Sciences®, chatted with John Dunlop, PHD, chief scientific officer, Aliada Therapeutics, at #BIO2024 https://lnkd.in/ehKRgPPm

The blood–brain barrier has proven to be a significant obstacle for drug administration in the past. However, being able to traverse this barrier and treat diseases that affect the brain, such as Alzheimer's disease, is getting slightly easier thanks to innovative technology like Aliada Therapeutics' MODEL platform. To learn more about this exciting new tool and the potential impact it may have on therapeutic delivery for brain-related conditions, Joe Petroziello, EVP, Global Medical Affairs & Corporate Development, MJH Life Sciences®, chatted with John Dunlop, PHD, chief scientific officer, Aliada Therapeutics, at #BIO2024 https://lnkd.in/ehKRgPPm

Ahmed Elhusseiny Area Head, Asia Pacific, Roche Pharma, underscored the broader implications: "As two-thirds of global vision loss affects the Asia-Pacific region, advancing treatments for conditions like PCV is imperative. These interim results highlight Vabysmo’s potential to significantly improve outcomes for patients and exemplify Roche’s commitment to eye health innovation in the region."

As many of you know, endometriosis is more than a research focus for me, it’s personal. I have it. It runs in my family. When my young daughter sees me in pain, she asks “mommy, will your medicine be ready in time for me?” With today’s announcement, I can more confidently tell her: yes, sweetheart, it will be. We have spent the past 6 years trying to dismantle the assumption that the ovary should just be allowed to stop working in midlife. And now we are building on our success with our pioneering ovarian health work to address one of the other biggest challenges that hinder women’s ability to thrive, which is pelvic pain and chronic inflammation from conditions like endometriosis. Our novel JNKi program has the potential to eradicate endometriosis, not just paper over its symptoms. This will be a game changer for the #oneinten women who live with this debilitating condition. I am proud to be working with the most incredible team of drug developers at Celmatix Therapeutics and academic collaborators at Baylor College of Medicine to relegate this terrible disease to the dustbin of history. 💪 #endendo #endometriosis #drugdiscovery #inflammation #pain #innovation #womenshealth

Eli Lilly just as active on the deal front as GSK... At least in advanced therapies. This was from last week but interesting to see Eli Lilly's deal with QurAlis for QRL-204, their ASO program for ALS and dementia. Eli Lilly is also quite active in making deals across the advanced therapies landscape. ALS is an indication that has a bit of attention across advanced therapies. WaVe Life Sciences had a program with Takeda (discontinued due to lack of efficacy signal in early clinical). There are also a number of companies approaching the indication with AAV-based approaches. While advanced therapies are exciting and hold tremendous promise, there's something to be said for "safer" bets and antisense oligos sure look to be that within the realm of "advanced" therapies at least. Keep an eye out for a partnership map we're putting together in the oligo space and in the meantime, reach out to chat all things pipeline, strategy, or production / manufacturing related! #ASO #drugdevelopment #healthcare https://lnkd.in/gniQHpJt

🗞 Breaking news 🗞 🧠 Following in the footsteps of other leaders in innovative #Alzheimer's treatments from Eisai Co., Ltd. and Biogen, Eli Lilly and Company's Kisunla is US FDA-approved. Strategic impacts to the treatment landscape include: ➕ Another Treatment Option: Kisunla/donanemab joins a new class of Alzheimer’s treatments (with Leqembi; Aduhelm) known as anti-amyloid monoclonal antibodies, targeting amyloid plaques in the brain.  ⬅ Early Intervention: Kisunla has shown promise in slowing cognitive decline by about 35% in patients with early-stage Alzheimer’s; underscoring the importance of early diagnosis and intervention, thus, the rationale for shifting the focus of treatment strategies to earlier stages. 💲 Cost and Accessibility: Less frequent infusions compared to other drugs, could lower treatment costs, improve accessibility, and may influence HCPs and insurers preferences vs. other options. 🛡 Safety and Efficacy: While Kisunla has demonstrated efficacy it also comes with potential side effects, such as brain swelling and bleeding. The balance of risk/benefits will be crucial in determining its adoption and uptake in treatment protocols. 📈Market Dynamics: The approval may intensify competition, driving further innovation and development in Alzheimer’s treatments. This competitive landscape may lead to more advanced and effective therapies in the future. #AlzheimersDisease #Lilly #Kisunla #ALZ #Neuroscience #NeurodegenerativeDisease #NDD #RegulatoryAffairs #Pharma #Healthcare

💊 Exciting Collaboration Alert: AbbVie Partners with Celsius Therapeutics! 🌟 AbbVie is joining forces with Celsius Therapeutics to develop cutting-edge treatments for inflammatory bowel disease (IBD), aiming to enhance patient outcomes and advance medical research in this critical area. 🌐 🔍 Key Highlights: -Strategic Collaboration: AbbVie and Celsius Therapeutics will leverage their combined expertise to innovate IBD treatments, potentially transforming the therapeutic landscape. -Focus on Humira: With Humira's legacy in treating IBD, this partnership aims to build on its success and introduce novel therapies. -Research and Development: The collaboration underscores the commitment to advancing R&D efforts, exploring new avenues for addressing complex medical conditions like IBD. This partnership is a significant step forward in the fight against IBD, promising innovative solutions and improved quality of life for patients worldwide. Stay tuned for more updates on this groundbreaking collaboration! 🚀 #AbbVie #CelsiusTherapeutics #IBD #Humira #MedicalInnovation #HealthcarePartnership #Biotech #ResearchAndDevelopment #PatientCare #HealthcareAdvancements

🔬 Celmatix announced a new drug development program targeting endometriosis through a novel Jun-N-terminal kinase (JNK) inhibitor. The therapeutic candidate, developed using Baylor College of Medicine‘s DNA-Encoded Chemistry Technology platform, aims to address pain and inflammation associated with endometriosis. 🤝 💬 "Despite impacting one-in-ten women and girls, to date there have been no disease-altering, first-line medications brought to market to treat endometriosis. As someone who has been impacted by endometriosis since my first period, I can relate to the burden that this debilitating disease places on individuals, families, employers, and communities. Thanks to our decade-long multi-omics initiative, our research group was early in recognizing that inflammation is core to the pathophysiology of endometriosis and may explain why it predisposes women for so many other health conditions down the road." Dr Piraye Beim, Celmatix Founder & CEO #femtech #womenshealth #womenshealthinnovation #health #healthcare #endometriosis #periodpain #menstruation #drug #drugdevelopment #partnership #launch

🚀 Novo Nordisk Expands Partnership with Valo Health for Groundbreaking Cardiometabolic Therapies! 🌍 Novo Nordisk A/S has significantly enhanced its collaboration with Valo Health, Inc., aiming to revolutionize treatments for obesity, type 2 diabetes, and cardiovascular diseases. This strategic partnership builds on their initial agreement from September 2023 and introduces a remarkable financial commitment of up to $190 million in near-term payments! 💰 Key Highlights: 🔹 Expansion of drug programs from 11 to 20 new initiatives 🔹 Potential milestone payments for Valo Health reaching $4.6 billion 🔹 Utilization of Valo’s Opal Computational Platform powered by AI for advanced drug discovery Both companies are on track to identify novel therapeutic targets that promise more effective treatments. With a shared vision and robust investment in research, they are set to make significant strides in combating chronic diseases that affect millions globally. Stay tuned as this partnership paves the way for innovative solutions that could transform patient care! #AIinHealthcare #CardiometabolicTherapies #HealthcareAdvancements #NovoNordisk #Partnership #Pharma #PharmaceuticalCompanies #PharmaceuticalInnovation #ValoHealth #MarketAccess #MarketAccessToday